Entegris Inc vs Tempus AI — how do they compare? Entegris Inc trades at $163.87 (market cap $25.41B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.24% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Tempus AI for 22 Days on average.
| ENTG | TEM | |
|---|---|---|
Market Cap | $25.41B | $12.77B |
Volume | 2,160,232 | 8,980,490 |
Sector | Technology | Broad Market / Factor |
52-Week High | $184.00 | $99.28 |
52-Week Low | $68.80 | $41.55 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $28.62B | $13.40B |
Dividend Yield | 0.24% | — |
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.82% today, with strong technical momentum as moving averages signal bullish alignment. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $0.93 versus $0.82, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B in 2025, while net income margin improved to 9.18% in 2026 projections. Recent institutional buying includes BlackRock's $3.68 billion position, reflecting confidence in Entegris' advanced materials leadership.
Outlook remains positive with analyst consensus target of $182.43 suggesting 12.5% upside, supported by 70% buy ratings. Key risks include high valuation multiples (P/E 83.16) and semiconductor cycle sensitivity. The upcoming Q3 earnings on October 29, 2026, and Investor Day on November 9, 2026, are critical catalysts for confirming growth trajectory amid competitive pressures.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →